Publications
B
Applications for an engineered Protein-G variant with a pH controllable affinity to antibody fragments,
Bailey, L. J., Sheehy K. M., Hoey R. J., Schaefer Z. P., Ura M., and Kossiakoff A. A.
, J Immunol Methods, Volume 415, p.24-30, (2014)
A
Quaternary structure independent folding of voltage-gated ion channel pore domain subunits.,
Arrigoni, Cristina, Lolicato Marco, Shaya David, Rohaim Ahmed, Findeisen Felix, Fong Lam-Kiu, Colleran Claire M., Dominik Pawel, Kim Sangwoo S., Schuermann Jonathan P., et al.
, Nat Struct Mol Biol, 2022 Jun, Volume 29, Issue 6, p.537-548, (2022)
Pages
- « first
- ‹ previous
- 1
- 2
- 3
- 4
Publications
- Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A. thaliana and P. sativum.
- Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.
- Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes.
- Engineering of a synthetic antibody fragment for structural and functional studies of K+ channels.
- Isoform- and ligand-specific modulation of the adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder.
- Quaternary structure independent folding of voltage-gated ion channel pore domain subunits.
- Structural basis for assembly and lipid-mediated gating of LRRC8A:C volume-regulated anion channels.
- Structure of an AMPK complex in an inactive, ATP-bound state.
- Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.
- Structure, sequon recognition and mechanism of tryptophan C-mannosyltransferase.
- Structures of ABCB4 provide insight into phosphatidylcholine translocation.
- Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
- Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.
- Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.